rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Harvard Bioscience, Inc.

HBIO · Nasdaq

Health CareLife-science toolsIn trend

HBIO stood above a rising 150-day average in 28 of the last 52 weekly readings, including each of the last 8 weeks. It is 23.8% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
8 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$405K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
35 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$390KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
William SniderDirectorbought8,475at $4.8517 Mar 2026filed 18 Mar 2026
Stephen J. DenelskyDirectorbought10,000at $4.8717 Mar 2026filed 18 Mar 2026
John D. DukeChief Executive Officerbought5,000at $5.0116 Mar 2026filed 17 Mar 2026
William SniderDirectorbought12,525at $4.9916 Mar 2026filed 18 Mar 2026
Mark T. FrostChief Financial Officerbought5,000at $5.0016 Mar 2026filed 1 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders35+1 on the quarter
New · exited5 · 3
Reported value$9.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
WEBER CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026310,861$1.9M-9,176−2.9%
Meros Investment Management, LPadded · filed 14 Aug 2026182,992$1.1M+64,470+54.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026169,625$1.0M+6,312+3.9%
NANO CAP NEW MILLENNIUM GROWTH FUND L Padded · filed 14 Aug 2026143,082$880K+25,582+21.8%
CORSAIR CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 2026122,810$755K-2,000−1.6%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026114,545$704K+428+0.4%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202699,327$611K-2,100−2.1%
BlackRock, Inc.reduced · filed 7 Aug 202661,834$380K-392−0.6%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202647,555$293K-11,956−20.1%
Mink Brook Asset Management LLCnew · filed 14 Aug 202633,369$205K+33,369
31 Mar 2023 – 30 Jun 2026
366186Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Katherine A. Eade Company insiderDirector · last 9 Jun 20261 · 0
Robert E. Gagnon Company insiderDirector · last 9 Jun 20266 · 12
Seth Benjamin Benson Company insiderDirector · last 9 Jun 20260 · 0
Stephen J. Denelsky Company insiderDirector · last 9 Jun 20261 · 0
William Snider Company insiderDirector · last 9 Jun 20262 · 0
John D. Duke Company insiderChief Executive Officer · last 20 Mar 20261 · 0
Mark T. Frost Company insiderChief Financial Officer · last 20 Mar 20261 · 0
James W. Green Company insiderDirector · last 15 Aug 202518 · 6
Jennifer Cote Company insiderChief Financial Officer · last 19 Mar 20250 · 0
Alan I. Edrick Company insiderDirector · last 21 May 20243 · 0
Bertrand Loy Company insiderDirector · last 21 May 202414 · 0
Thomas W. Loewald Company insiderDirector · last 21 May 20241 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202557.7%
Operating profit marginFY 2025 · to 31 Dec 2025-56.1%
Free cash flow marginFY 2025 · to 31 Dec 20256.3%
Return on capital employedFY 2025 · to 31 Dec 2025-83.6%
Debt to equityFY 2025 · to 31 Dec 20252.61×
Interest coverFY 2025 · to 31 Dec 2025-13.49×
Research spendFY 2025 · to 31 Dec 202510.2%
Share count trendFY 2025 · to 5 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$8.6M
Free cash flowFY 2025 · to 31 Dec 2025$5.5M

Analyst forecasts

No analyst forecasts yet.